Table 1: Selection,
Design & Construction of HSV - based Oncolytic Viruses Table 2: Selection,
Design & Construction of Adenovirus - based Oncolytic Viruses Table 3: Selection,
Design & Construction of Vaccinia Virus - based Oncolytic Viruses Table 4: Selection,
Design & Construction of Vesicular Stomatitis Virus - based Oncolytic Viruses Table 5: Selection,
Design & Construction of Newcastle Disease Virus - based Oncolytic Viruses Table 6: Selection,
Design & Construction of Various Virus - based Oncolytic Viruses Table 7: Current Company - Sponsored
Clinical Trials of T - Vec Table 8:
Clinical Trials of ColoAd1 Table 9:
Clinical Trials with JX - 594 Table 10:
Clinical Trials with GL - ONC1 Table 11:
Clinical Trials of CAVATAK (CVA21) Table 12:
Clinical Trials with MV - NIS Table 13: Overview of Oncolytic Viruses by Development Phase & Virus Family Table 14: Profile of Approved and Marketed Oncolytic Viruses Table 15: Pivotal Study
Design of Oncolytic Viruses in Late Stage Development Based on
Previous Clinical Results Table 16: Approved Indications of Immune Checkpoint Inhibitors Table 17: Active
Clinical Studies of Oncolytic Viruses in Combination with Immune Checkpoint Inhibitors (ICI) Table 18: Planned
Clinical Studies of Oncolytic Viruses in Combination with Immune Checkpoint Inhibitors (ICI) Table 19: Active or Planned
Clinical Studies of Oncolytic Viruses in Combination with Other Anti-Cancer Therapeutics Table 20: Pattern of Transgenes in Oncolytic Viruses in Relation to Development Phase Tables 21a and 21b: Indications and Frquency and Way of Administration of Oncolytic Viruses in Active and / or Positive Completed
Clinical Studies Table 22: Small and Medium Pharma & Biotech as Partner for Regional Co-Development of Oncolytic Viruses Table 23: Immuno - Oncology Portfolio of Major Pharma & Biotech with Interest in Oncolytic Viruses Table 24: Interests of Major Pharma & Biotech in Oncolytic Viruses Table 25: First Generation Oncology Virus Companies and their Sources of Technology Table 26: Second Generation Oncology Virus Companies and their Sources of Technology Table 27: Third Generation Oncology Virus Companies and their Sources of Technology Table 28: Fourth Generation Oncology Virus Companies and their Sources of Technology Table 29: Grants, Credits & Donations Table 30: Financing by Venture Capital, Private Equity and Other Private Placements Table 31: Collaboration & Licensing Agreements Table 32: Companies Listed on Stock Exchange & Offerings Table 33: Mergers & Acquisitions